Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Introduction: Subjective cognitive decline (SCD) has been proposed as a potential preclinical stage of Alzheimer's disease (AD). Nevertheless, the genetic and biomarker profiles of SCD individuals remain mostly unexplored. Methods: We evaluated apolipoprotein E (APOE) ε4's effect in the risk of presenting SCD, using the Fundacio ACE Healthy Brain Initiative (FACEHBI) SCD cohort and Spanish controls, and performed a meta‐analysis addressing the same question. We assessed the relationship between APOE dosage and brain amyloid burden in the FACEHBI SCD and Alzheimer's Disease Neuroimaging Initiative cohorts. Results: Analysis of the FACEHBI cohort and the meta‐analysis demonstrated SCD individuals presented higher allelic frequencies of APOE ε4 with respect to controls. APOE dosage explained 9% (FACEHBI cohort) and 11% (FACEHBI and Alzheimer's Disease Neuroimaging Initiative cohorts) of the variance of cerebral amyloid levels. Discussion: The FACEHBI sample presents APOE ε4 enrichment, suggesting that a pool of AD patients is nested in our sample. Cerebral amyloid levels are partially explained by the APOE allele dosage, suggesting that other genetic or epigenetic factors are involved in this AD endophenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014 · cited 1×
“An SCD population represents a subset of cognitively normal individuals with self-reported cognitive impairment [4].”
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 1×
“30e24] was unexpected taking into account the protective role of APOE ε2 in AD [34].”
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242
Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · cited 1×
“Several studies have detected higher cerebral amyloid burden in AD and MCI patients compared with cognitively normal individuals [13–15] and also in AD compared with MCI patients [13], but studies evaluating amyloid pathology in SCD have provided inconsistent results [15,16].”
Testing the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550
Lopez, O. L., Jagust, W. J., Dulberg, C., Becker, J. T., DeKosky, S. T., Fitzpatrick, A., Breitner, J., Lyketsos, C., Jones, B., Kawas, C., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.10.1394 · Cited by 477
Subjective cognitive complaints and amyloid burden in cognitively normal older individuals
Amariglio, R. E., Becker, J. A., Carmasin, J., Wadsworth, L. P., Lorius, N., Sullivan, C., Maye, J. E., Gidicsin, C., Pepin, L. C., Sperling, R. A., et al. (2012) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2012.08.011 · Cited by 472 · cited 1×
“Several studies have detected higher cerebral amyloid burden in AD and MCI patients compared with cognitively normal individuals [13–15] and also in AD compared with MCI patients [13], but studies evaluating amyloid pathology in SCD have provided inconsistent results [15,16].”
The age factor in Alzheimer’s disease
Guerreiro, R., & Bras, J. (2015) · Genome Medicine · doi:10.1186/s13073-015-0232-5 · Cited by 415
Ramanan, V. K., Risacher, S. L., Nho, K., Kim, S., Shen, L., McDonald, B. C., Yoder, K. K., Hutchins, G. D., West, J. D., Tallman, E. F., et al. (2015) · Brain · doi:10.1093/brain/awv231 · Cited by 133
Lacour, A., Espinosa, A., Louwersheimer, E., Heilmann, S., Hernández, I., Wolfsgruber, S., Fernández, V, Wagner, H., Rosende-Roca, M., Mauleón, A., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.18 · Cited by 101
Self-citationFernández-Blázquez, M. A., Ávila-Villanueva, M., Maestú, F., & Medina, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150956 · Cited by 98
Bangen, K. J., Initiative, F. T. A. D. N., Clark, A. L., Werhane, M., Edmonds, E. C., Nation, D. A., Evangelista, N., Libon, D. J., Bondi, M. W., & Delano-Wood, L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150900 · Cited by 51
Research works printed but not linked: 34
- 10.1016/S1474-4422(09)70299-6 · DOI · Paper page
- 10.1016/S1474-4422(12)70291-0 · DOI · Paper page
- 10.1126/science.8346443 · DOI · Paper page
- Moreno‐Grau S, 2016, Genome research in pre‐dementia stages of Alzheimer's disease, Expert Rev Mol Med, 18, e11, 10.1017/erm.2016.12 · DOI
- 10.1016/j.neurobiolaging.2010.09.003 · DOI
- 10.1016/S0197-4580(01)00254-8 · DOI
- 10.1016/S0140-6736(06)69113-7 · DOI · Paper page
- 10.1038/mp.2013.19 · DOI · Paper page
- 10.1016/S1474-4422(13)70044-9 · DOI · Paper page
- 10.1016/j.jalz.2015.03.003 · DOI · Paper page
- Rodriguez‐Gomez O, 2017, FACEHBI: A prospective study of risk factors, biomarkers and cognition in a cohort of individuals with subjective cognitive decline. Study rationale and research protocols, J Prev Alz Dis, 4, 100
- 10.1371/journal.pone.0076436 · DOI
- 10.1001/archneur.56.3.303 · DOI · Paper page
- 10.1111/j.1365-2796.2004.01388.x · DOI · Paper page
- 10.1001/archneur.64.3.416 · DOI · Paper page
- 10.1038/mp.2013.86 · DOI · Paper page
- Martínez‐Larrad MT, 2005, [Prevalence of the metabolic syndrome (ATP‐III criteria). Population‐based study of rural and urban areas in the Spanish province of Segovia], Med Clin (Barc), 125, 481
- 10.1161/hy0202.103439 · DOI
- 10.1016/j.jalz.2010.03.007 · DOI · Paper page
- 10.1016/j.jalz.2010.03.003 · DOI · Paper page
- 10.1086/519795 · DOI · Paper page
- 10.1001/archgenpsychiatry.2010.30 · DOI · Paper page
- 10.1016/j.jalz.2011.03.003 · DOI · Paper page
- 10.1038/jcbfm.2015.85 · DOI
- 10.1161/01.STR.0000259816.31370.44 · DOI · Paper page
- 10.1038/nrneurol.2015.10 · DOI · Paper page
- 10.3233/JAD-150189 · DOI · Paper page
- Abdulrab K, 2008, Subjective memory impairment. A review of its definitions indicates the need for a comprehensive set of standardised and validated criteria, Eur Psychiatry, 23, 10.1016/j.eurpsy.2008.02.004 · DOI · Paper page
- Zwan MD, 2015, Subjective memory complaints in APOE ɛ4 carriers are associated with high amyloid‐β burden, J Alzheimers Dis, 49
- 10.1016/j.jalz.2016.06.093 · DOI
- 10.2967/jnumed.115.161893 · DOI
- 10.3233/JAD-160667 · DOI
- 10.1212/WNL.57.12.2217 · DOI · Paper page
- 10.1016/j.jagp.2014.07.009 · DOI
Cited by
The characterisation of subjective cognitive decline
Jessen, F., Amariglio, R. E., Buckley, R. F., van der Flier, W. M., Han, Y., Molinuevo, J. L., Rabin, L., Rentz, D. M., Rodriguez-Gomez, O., Saykin, A. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30368-0 · Cited by 1,389
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease
Wang, X., Huang, W., Su, L., Xing, Y., Jessen, F., Sun, Y., Shu, N., & Han, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00395-3 · Cited by 265
Paranjpe, M. D., Chen, X., Liu, M., Paranjpe, I., Leal, J. P., Wang, R., Pomper, M. G., Wong, D. F., Benzinger, T. L. S., & Zhou, Y. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101795 · Cited by 51
Yue, Q., Leng, X., Xie, N., Zhang, Z., Yang, D., & Hoi, M. P. M. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70079 · Cited by 48
Metadata
- Authors
- Moreno–Grau, S., Rodríguez‐Gómez, O., Sanabria, Á., Pérez‐Cordón, A., Sánchez‐Ruiz, D., Abdelnour, C., Valero, S., Hernández, I., Rosende‐Roca, M., Mauleón, A., Vargas, L., Lafuente, A., Gil, S., Santos‐Santos, M. Á., Alegret, M., Espinosa, A., Ortega, G., Guitart, M., Gailhajanet, A., de Rojas, I., Sotolongo‐Grau, Ó., Ruiz, S., Aguilera, N., Papasey, J., Martín, E., Peleja, E., Initiative, A. D. N., Lomeña, F., Campos, F., Vivas, A., Gómez‐Chiari, M., Tejero, M. Á., Giménez, J., Serrano‐Ríos, M., Orellana, A., Tárraga, L., Ruiz, A., Boada, M., FACEHBI study group, Abdelnour, C., Aguilera, N., Alegret, M., Berthier, M., Boada, M., Buendia, M., Bullich, S., Campos, F., Cañabate, P., Cuevas, C., de Rojas, I., Espinosa, A., Gailhajenet, A., Diego, S., Gil, S., Giménez, J., Gismondi, R., Gómez‐Chiari, M., Guitart, M., Hernández‐Olasagarre, B., Hernández, I., Ibarria, M., Lafuente, A., Lomeña, F., Martín, E., Martínez, J., Mauleón, A., Monté, G., Moreno, M., Moreno‐Grau, S., Núñez, L., Orellana, A., Ortega, G., Páez, A., Pancho, A., Pavía, J., Pelejà, E., Pérez‐Cordon, A., Pérez‐Grijalba, V., Pesini, P., Preckler, S., Rodríguez‐Gómez, O., Romero, J., Rosende‐Roca, M., Ruiz, A., Ruiz, S., Sanabria, A., Sánchez‐Ruiz, D., Santos‐Santos, M. A., Sarasa, M., Sotolongo‐Grau, O., Tárraga, L., Tejero, M. A., Torres, M., Valero, S., Vargas, L., & Vivas, A.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2017-11-20
- Volume
- 14
- Issue
- 5
- Pages
- 634-643
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2769567977
- Cited by
- 41
- References
- 14
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- Funders
- Alzheimer's Disease Neuroimaging Initiative (U01 AG024904)
- U.S. Department of Defense (W81XWH‐12‐2‐0012)
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- Canadian Institutes of Health Research
- Northern California Institute for Research and Education
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.